Completed PHASE3 INTERVENTIONAL 2-arm NCT00810030

FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR (FER-IBD-COR)

Select A Multi-centre Randomised Prospective Open-label Study to Investigate the Efficacy & Safety of a Standardised Correction Dosage Regimen of i.v. Ferric Carboxymaltose Versus Iron Sucrose for Treatment of Iron Deficiency Anaemia in Patients With Inflammatory Bowel Disease

Sponsor: ClinStar, LLC

Conditions Anemia Crohn's Disease Inflammatory Bowel Disease Iron Deficiency Iron-Deficiency Anemia Ulcerative Colitis

Interventions Ferric carboxymaltose Iron Sucrose

Updated 7 times since 2017 Last updated: Dec 19, 2012 Started: Oct 31, 2008 Primary completion: Dec 31, 2009 Completion: Apr 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Anemia and Crohn's Disease and is currently completed. ClinStar, LLC leads this study, which shows 7 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Oct 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Oct 2021 [monthly]

Completed PHASE3
May 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — May 2020 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Oct 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ClinStar, LLC
Parexel
Vifor Pharma

Data source: Vifor Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vienna, Austria